Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
2500
Trial Sponsor
Clinical Trial Start Date
January 14, 2023
0Primary Completion Date
December 1, 2025
0Study Completion Date
December 11, 2026
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Drug0
Interventional Trial Phase
Phase 30
Official Name
HUMAN ALBUMIN IN HEART FAILURE - DIORASIS TRIAL0
Last Updated
October 8, 2024
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Other attributes
Intervention Treatment
Human albumin0
Study summary
Patients hospitalized for acute decompensation of CHF are usually complicated by worsening renal function (WRF) which leads to diuretic resistance and inadequate decongestion as well as poor prognosis. WRF has been attributed to a reflex renal vasoconstriction elicited by intravascular volume depletion during brisk diuresis. The investigators hypothesize that CHF patients with hepatic dysfunction are more prone to WRF due to poor albumin production. This sub-group of CHF patients may benefit more (increased diuretic efficacy and protected against worsening renal function) by the use of IV loop diuretics in combination with an intravascular volume expander such as IV Human Albumin.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.